<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01988779</url>
  </required_header>
  <id_info>
    <org_study_id>45566</org_study_id>
    <nct_id>NCT01988779</nct_id>
  </id_info>
  <brief_title>Oral Versus Topical Antibiotics for Chronic Rhinosinusitis Exacerbations</brief_title>
  <official_title>Oral Versus Topical Antibiotic Therapy for Treatment of Chronic Rhinosinusitis Exacerbations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to treat patients with a diagnosis of chronic rhinosinusitis
      (CRS) and a history of bilateral endoscopic sinus surgery during times of worsening symptoms
      and signs of acute infection on nasal endoscopy with one of two treatments: (1) oral
      antibiotics and twice daily intranasal saline irrigations or (2) oral placebo and twice daily
      intranasal antibiotic irrigations. The two treatments will be compared to see if there is any
      difference in patient outcomes. This will help guide treatment strategies for patients with
      CRS in the future.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      See brief summary.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Rhinosinusitis Disability Index (RSDI) scores</measure>
    <time_frame>14 days after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endoscopy findings using POSE scores</measure>
    <time_frame>14 days after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the total bacterial community following treatment as determined by RNA pyrosequencing.</measure>
    <time_frame>14 days after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in aerobic bacterial cultures performed via traditional microbiology plating techniques</measure>
    <time_frame>14 days after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Chronic Rhinosinusitis</condition>
  <arm_group>
    <arm_group_label>oral placebo with nebulized intranasal levofloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo oral tablet by mouth daily for 14 consecutive days along with nebulized levofloxacin 125 mg twice daily for 14 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oral antibiotics with nebulized intranasal placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Levofloxacin 500 mg by mouth once daily for 14 consecutive days, along with intranasal placebo solution twice daily for 14 consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral levofloxacin</intervention_name>
    <arm_group_label>oral placebo with nebulized intranasal levofloxacin</arm_group_label>
    <arm_group_label>oral antibiotics with nebulized intranasal placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nebulized levofloxacin</intervention_name>
    <arm_group_label>oral placebo with nebulized intranasal levofloxacin</arm_group_label>
    <arm_group_label>oral antibiotics with nebulized intranasal placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults (age â‰¥ 18).

          2. Diagnosis of CRS.

          3. Worsening sinonasal symptoms.

          4. Previous bilateral endoscopic sinus surgery (ESS) (including maxillary antrostomy and
             anterior ethmoidectomy).

          5. English speaking.

          6. Open sinuses (open middle meatus bilaterally; determined on endoscopy).

          7. Positive sinonasal culture (1+ or greater) with sensitivity to one of the pre-chosen
             antibiotic regimens.

        Exclusion Criteria:

          1. Patients &lt; 18 years of age.

          2. Treatment with systemic or topical antibiotics within the last 1 month.

          3. Pregnant women.

          4. Non-English speaking persons.

          5. Systemically ill at initial visit necessitating treatment prior to culture data.

          6. Allergies to chosen susceptible antibiotics.

          7. Sinonasal culture with less than 1+ growth.

          8. Multiple organisms grown on culture that are not sensitive to a single antibiotic.

          9. Patients with ciliary function disorders (cystic fibrosis, Kartagener's syndrome,
             ciliary dyskinesia).

         10. Patients with immunodeficiencies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li-Xing Man, MD, MPA, Msc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li-Xing Man, MD</last_name>
    <phone>585-758-5700</phone>
    <email>Li-Xing_Man@urmc.rochester.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Rochester Department of Otolaryngology Head and Neck Surgery</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alexis Strohl, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Li-Xing Man, MSc, MD, MPA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2013</study_first_submitted>
  <study_first_submitted_qc>November 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2013</study_first_posted>
  <last_update_submitted>October 26, 2017</last_update_submitted>
  <last_update_submitted_qc>October 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Li-Xing Man</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

